Medicenna Strengthens Intellectual Property Portfolio with Five Patents Granted for its IL-2 and IL-4 Superkines

Core Insights - Medicenna Therapeutics Corp. has been granted five patents that enhance its intellectual property position for IL-2 and IL-4 Superkine platforms, which are crucial for its clinical and preclinical programs [1][2]. Patent Details - The newly granted patents cover various aspects including composition, formulation, combination, use, and therapeutic applications of IL-2 and IL-4 Superkines, with expiration dates ranging from 2033 to 2040 [2]. - Notable patents include coverage for IL-2 superagonists in combination with anti-PD-1 antibodies, which is significant for the ongoing Phase 1/2 ABILITY-1 study of MDNA11 [2][4]. - A novel formulation of bizaxofusp (MDNA55) has also received patent protection, which is used in a Phase 2b clinical trial for recurrent glioblastoma, enhancing its commercial exclusivity [2][3]. Company Overview - Medicenna is focused on developing novel immunotherapies, particularly Superkines, for oncology and autoimmune diseases [3]. - The company’s lead asset, MDNA11, is a long-acting IL-2 Superkine designed to preferentially stimulate cancer-fighting T cells and NK cells [3]. - Bizaxofusp has been involved in five clinical trials with over 130 patients and has received FastTrack and Orphan Drug status from the FDA and EMA [3]. Intellectual Property Portfolio - Medicenna's global intellectual property portfolio now includes 86 granted or allowed patents, supporting a diverse clinical pipeline [2].